TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00676884
Drug: Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mgs s.c. b.i.d.
Study: NCT00676884
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mL s.c. b.i.d.
Study: NCT00002784
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
Study: NCT00002784
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
Study: NCT00002784
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
Study: NCT00002784
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
Study: NCT03743922
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule
Study: NCT00350961
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00232141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02882087
Drug: Placebo plus MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
Study: NCT01188317
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: repeated daily doses
Study: NCT03918135
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400mg of ibuprofen(intrafen 400mg/4ml Gen ilaç sanayi, Turkey) intravenous (IV) was given 100 patients~Other Names:~Dorifen
Study: NCT01088256
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
Study: NCT00849056
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo weekly subcutaneous injection
Study: NCT04415268
Drug: CFTR Modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care: Lumacaftor with Ivacaftor or Tezacaftor combined with Ivacaftor.~For children between 6 and 11 years of age, Lumacaftor 400 mg combined with Ivacaftor 500 mg in total per day, divided into 2 doses per day; for those over 11 years of age, Tezacaftor 100 mg combined with Ivacaftor 150 mg in the morning, adding a dose of Ivacaftor 150 mg at night.~https://www.clinicaltrialsregister.eu/ctr-search/trial/2019-000833-37/ES
Study: NCT00051974
Drug: VELCADE™ (bortezomib) for Injection (formerly PS-341)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04028492
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID
Study: NCT02181699
Drug: KHK2823
Approvals — FDA: no, EMA: no, PMDA: no
Description: single agent KHK2823
Study: NCT04006860
Drug: SHC014748M Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHC014748M Capsules: 200mg
Study: NCT01368081
Drug: Placebo (low dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT01368081
Drug: Placebo (high dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT01088256
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients get one pill of placebo (sugar-pill) per day for 8 days.
Study: NCT02098278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01351753
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills and capsules for metformin, orlistat and topiramate
Study: NCT03456531
Drug: NSAIDs ibubrofen,Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical treatment as NSAIDs ibubrofen,Aspirin
Study: NCT01829399
Drug: Bupivacaine with Epinephrine
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
Study: NCT01829399
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02729623
Drug: Kite Systems cannaHALER cannabis Inhaler.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02750150
Drug: Fresh-frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00359151
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
Study: NCT00359151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
Study: NCT01710631
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03034382
Drug: Lidocaine Hydrochloride 1% and epinephrine 1:400,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
Study: NCT00058006
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02749630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to UTTR1147A administered intravenously
Study: NCT00836069
Drug: No drug name provided by Sponsor; drug referenced as PD 0332334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental study drug for generalized anxiety disorder, oral tablet, at a total daily dose of 450mg or 600mg, twice daily for 8 weeks and then 2 weeks of dose tapering.
Study: NCT00836069
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: inactive substance, oral tablet, once per day, for 10 weeks.
Study: NCT02214433
Drug: Placebo IV Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: A sterile IV solution of 5% dextrose in water
Study: NCT02214433
Drug: Placebo Tablet or Capsule
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
Study: NCT03739411
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo chemotherapy for cancer outside of this study.
Study: NCT02647320
Drug: DS-8500a 25mg
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8500a 25mg tablet for oral administration
Study: NCT02647320
Drug: Placebo Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching DS-8500a tablet for oral administration
Study: NCT02647320
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching sitagliptin over-capsule for oral administration
Study: NCT02049151
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
Study: NCT02049151
Drug: Cyclophosphamide (CPA)
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m\^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
Study: NCT03057977
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT04591444
Drug: Glass Ionomer Sealant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Following the manufacturer's recommendations, prophylaxis and prior drying of the treated surface was carried out, the product was also dispensed and manipulated for 15 s until a homogeneous mixture was obtained, applied with a micro brush and light-cured for 20 s.
Study: NCT00681746
Drug: AZD6280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
Study: NCT00247585
Drug: Ethanol (Bourbon or Vodka)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02552641
Drug: Clarythromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03236233
Drug: PC786 - Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single doses
Study: NCT03236233
Drug: Placebo - Single doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of single doses
Study: NCT01999725
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules or matching suspension
Study: NCT01718444
Drug: Progestin
Normalized name: Progestin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01488201
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03236233
Drug: Placebo - Repeat doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safety and tolerability of repeat doses
Study: NCT04549051
Drug: Local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only local anesthetic into the coracohumeral ligament for adhesive capsulitis
Study: NCT01488201
Drug: KHK4827
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00946192
Drug: Transdermal 17Beta-estradiol, progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
Study: NCT00946192
Drug: Ethinyl Estradiol + Desogestrel
Normalized name: desogestrel / ethinyl estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
Study: NCT00379067
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03662516
Drug: Ethinyl estradiol (EE) and levonorgestrel (LN)
Normalized name: estradiol / ethinyl estradiol / levonorgestrel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Study: NCT00815893
Drug: Normal Saline 0.9%
Normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% Normal Saline 0.25ml/kg infusion for 10minues
Study: NCT02095704
Drug: paracetamol oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
Study: NCT02831517
Drug: BIIB074
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as specified in the treatment arm
Study: NCT02831517
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched Placebo
Study: NCT01353638
Drug: Dipeptiven (Alanyl-glutamine-dipeptide)
Normalized name: palmitoyl dipeptide-7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
Study: NCT06613919
Drug: Anti-Tuberculosis Treatment
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, weight adjusted anti-TB therapy for six months
Study: NCT06613919
Drug: Anti-Tuberculosis Treatment
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard, weight-adjusted anti-TB therapy for nine months
Study: NCT00708097
Drug: NaF
Normalized name: Renaf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride
Study: NCT00708097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03250325
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Study: NCT03549026
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive single oral dose of placebo capsule, 2 hours before operation and will be anesthetized with general anesthesia that includes, Induction of anesthesia will be done by intravenous fentanyl, 2 µg / kg and propofol 1 - 2 mg / kg. Endotracheal intubation will be achieved by cis-atracurium, 0.15 mg / kg. Maintenance of anesthesia will be done by isoflurane and cis-atracurium, 0.03 mg / kg on demand. Additional intraoperative analgesia will be consisted of administration of intravenous boluses of fentanyl, 50 µg according to the attending anesthesiologist's decision. At the end of surgery, muscle relaxation was reversed using neostigmine 0.05 mg / kg and atropine 0.01 mg / kg
Study: NCT02337764
Drug: TVP-1012 1mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVP-1012 1mg Tablets
Study: NCT01636843
Drug: NNC0109-0012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Study: NCT01636843
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously (s.c., under the skin), once weekly.
Study: NCT00964704
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
Study: NCT01345669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily
Study: NCT00141128
Drug: SS-RBX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03145948
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: It is administered orally.
Study: NCT04478448
Drug: Flupirava
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 200 mg Favipiravir
Study: NCT02191813
Drug: Seresis®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02191813
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00532623
Drug: Sequential
Normalized name: TABLET, SEQUENTIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles.
Study: NCT03928366
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: remifentanil
Study: NCT00206713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered SC once daily during the randomized retreatment phase.
Study: NCT03595397
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 patients will receive mid-thoracic epidural analgesia with a loading dose of 8 ml of 0.125 bupivacaine and 2 mcg/ml fentanyl, followed by continuous infusion of 8 ml/hour.
Study: NCT04375514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calculated volume to match active treatment by inhalation of nebulized solution
Study: NCT02624531
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACT and Fertility-sparing Treatment Strategy
Study: NCT00715208
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00412113
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/atorvastatin single pill combination 10/20 mg
Study: NCT00412113
Drug: Amlodipine besylate/atorvastatin calcium single pill combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine/atorvastatin single pill combination 5/20 mg
Study: NCT00715208
Drug: doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00526175
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2, i.v., day 22.
Study: NCT00526175
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Age \<1 year 1-2 years 2-3 years \> 3 years MTX 5 mg 8 mg 10 mg 12 mg
Study: NCT01755728
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
Study: NCT06712381
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carac (fluorouracil) Cream, 0.5% is used by adults to treat skin conditions on the face and front part of the scalp called solar keratosis or actinic keratosis.
Study: NCT01359501
Drug: Chinese medical treatment-LCH1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start to take the powder of Chinese herb-LCH1 3g\*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
Study: NCT01359501
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Start to take the powder of Placebo 3g\*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
Study: NCT01418742
Drug: Panitumumab, Doxycycline/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
Study: NCT01665391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to match active treatment group
Study: NCT00526175
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
Study: NCT00146068
Drug: Avonex/Zocor
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03395587
Drug: standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: temozolomide, fractionated radiochemotherapy
Study: NCT00432770
Drug: ARC1779
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03998254
Drug: V503
Normalized name: POUCH COMFORT PANEL NU-HOPE #EV5033-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9vHPV \[Types 6, 11, 16, 18, 31, 33, 45, 52, and 58\] L1 virus-like particle vaccine
Study: NCT00446173
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/kg IV Daily Over 4 Hours x 2 Days
Study: NCT04072887
Drug: QBW251
Approvals — FDA: no, EMA: no, PMDA: no
Description: QBW251 oral capsules (450, 300, 150, 75 and 25 mg) of identical appearance to ensure blinding administered twice a day (b.i.d) for 24 weeks
Study: NCT04072887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules administered twice a day for 24 weeks
Study: NCT04072887
Drug: COPD maintenance background therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fluticasone furoate, vilanterol and umeclidinium bromide
Study: NCT03487666
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine was selected for Arm B given the recent results from CREATE-X trial and the increasing use by the community (feasibility). Importantly, available data from other scenarios indicates that capecitabine does not have immunosuppressive effects
Study: NCT03980756
Drug: AD-206 20mg
Normalized name: zinc oxide 0.206 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT03980756
Drug: AD-206 40mg
Normalized name: zinc oxide 0.206 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet administered before the breakfast during 7 days
Study: NCT00864058
Drug: NEURONTIN® 400 mg capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Parke-Davis's marketed product
Study: NCT00009685
Drug: VRC4302
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04585347
Drug: ALZ-801 205 mg After Food
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01065272
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.~1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days
Study: NCT00335153
Drug: Levodopa-carbidopa intestinal gel
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
Study: NCT01417000
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes